As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices | Industry News
Amid competition from cheaper generics, Danish drugmaker Novo Nordisk on Monday announced price cuts of up to…
Boston to curb insurance coverage of GLP-1 drugs for city workers
The PEC voted unanimously on Tuesday to let the city change its Blue Cross Blue Shield of Massachusetts…
Ozempic Goes Generic —But Not in the US
A drug that helped turn Novo Nordisk into Europe’s most valuable company is about to lose its…
Coming Soon: ‘Wegovy HD’
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may…
What to Know about the Experimental GLP-1 Drug CagriSema
3 min read THESE DAYS, WHEN it comes to weight loss drugs, you’ve got a veritable buffet of…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
GLP-1 Patients Report New Side Effect—and It’s Worse Than ‘Ozempic Face’
Tatsiana Volkava/Getty Images A newly reported side effect of the popular GLP-1 weight loss drugs may be its…
Has anyone died from taking GLP-1 weight-loss drugs? – Baltimore Sun
Has anyone died from taking GLP-1 weight-loss drugs? Baltimore SunObesity Injectables Linked to Gallstone Disease Surge 조선일보GLP-1 Weight-Loss Drugs Linked…
Mounjaro and Wegovy ‘worse off than before’ warning
A Cambridge University study found people who stop taking weight loss jabs such as Mounjaro and Wegovy regain…
Weight loss jab users warned they could be ‘worse off than before’
Wegovy and Mounjaro are approved by the NHS for weight loss use (Image: OMaltseva via Getty Images) People…
Lost insurance coverage for GLP-1 weight-loss drugs? Tell us.
With health care spending on wildly popular GLP-1 drugs for weight loss soaring, local insurers got stricter this…